Aaron Mitchell

Aaron Mitchell is a health outcomes researcher at Memorial Sloan Kettering whose analyses of FDA oncology drug approvals, surrogate endpoints, and post-marketing evidence requirements have revealed gaps in the cancer drug regulatory framework. His research documenting the proportion of accelerated approvals lacking confirmatory evidence has informed debates about regulatory standards. His work on cancer drug pricing trends relative to clinical benefit has contributed to value-based oncology policy discussions.